Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Balance Sheet: Assets 

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Gilead Sciences Inc., consolidated balance sheet: assets

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Cash and cash equivalents 9,991 6,085 5,412 5,338 5,997
Short-term marketable debt securities 1,179 973 1,182 1,411
Accounts receivable, net 4,420 4,660 4,777 4,493 4,892
Inventories 1,710 1,787 1,507 1,618 1,683
Prepaid taxes 480 559
Equity securities 1,577 1,086
Other 995 729 1,774 2,141 2,013
Prepaid and other current assets 3,052 2,374 1,774 2,141 2,013
Current assets 19,173 16,085 14,443 14,772 15,996
Property, plant and equipment, net 5,414 5,317 5,475 5,121 4,967
Long-term marketable debt securities 1,163 1,245 1,309 502
Intangible assets, net 19,948 26,454 28,894 33,455 33,126
Goodwill 8,314 8,314 8,314 8,332 8,108
Other long-term assets 6,146 4,792 4,800 4,963 5,708
Long-term assets 39,822 46,040 48,728 53,180 52,411
Total assets 58,995 62,125 63,171 67,952 68,407

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Gilead Sciences Inc. current assets increased from 2022 to 2023 and from 2023 to 2024.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Gilead Sciences Inc. property, plant and equipment, net decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Gilead Sciences Inc. long-term assets decreased from 2022 to 2023 and from 2023 to 2024.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Gilead Sciences Inc. total assets decreased from 2022 to 2023 and from 2023 to 2024.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Gilead Sciences Inc. cash and cash equivalents increased from 2022 to 2023 and from 2023 to 2024.
Short-term marketable debt securities Amount of investment in marketable security, classified as current. Gilead Sciences Inc. short-term marketable debt securities increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Gilead Sciences Inc. accounts receivable, net decreased from 2022 to 2023 and from 2023 to 2024.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Gilead Sciences Inc. inventories increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.